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Voiding Dysfunction
Association of Metabolic Syndrome and Benign Prostate 
Enlargement in Young Korean Males 
Jee Hoon Jeong, Eun Tak Kim, Dae Kyung Kim
Department of Urology, Eulji University Hospital, Eulji University College of Medicine, Daejeon, Korea
Purpose: This study was designed to evaluate the association of metabolic syndrome 
and benign prostate enlargement in young Korean males. We analyzed the clinical data 
associated with metabolic syndrome and prostate volume in the study population.
Materials and Methods: We retrospectively analyzed the clinical data obtained from 
1,506 young men under the age of 60 who visited the health promotion center in our 
institution for routine checkups. The patients were interviewed with a questionnaire 
including the International Prostate Symptom Score (IPSS) and were evaluated by 
medical history, blood chemistry, digital rectal examination, and prostate volume via 
transrectal ultrasonography. The presence of metabolic syndrome was determined ac-
cording to the modified National Cholesterol Education Program Expert Panel on 
Detection, Evalution, And Treatment of High Blood Cholesterol in Adults criteria. We 
divided the subjects into two groups: those with metabolic syndrome and those without. 
Logistic regression analysis was carried out to determine which metabolic components 
were associated with an increased risk of benign prostate enlargement.
Results: Significant differences in prostate volume were noted between the groups. The 
prostate volumes were significantly larger in the metabolic syndrome group than in 
the non-metabolic syndrome group in all subgroups divided by age (in decades). 
However, no significant differences in IPSS or voiding or storage subscore were noted. 
In the multivariate regression analysis, only diabetes and obesity were identified as 
risk factors for benign prostate enlargement among the metabolic components.
Conclusions: Metabolic syndrome and prostate volume were significantly related, even 
in young males. Diabetes and obesity were identified as significant risk factors for be-
nign prostate enlargement in young males under the age of 60. 
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a prevalent disorder 
among older men and has received more attention as the 
average human lifespan has increased. In Korea, the prev-
alence of clinical prostatic hyperplasia was reported to 
range from 10.6% to 31% in men over 50 years of age, with 
an age-related increase [1,2]. 
The metabolic syndrome (MS) is a clinical constellation 
of metabolic abnormalities associated with an increased 
risk of cardiovascular disease. The major disorders in MS, 
which is characterized by insulin resistance and hyper-
insulinemia, are localized in muscle, fat tissue, and the liv-
er [3]. The components of this syndrome are type II diabetes 
mellitus, hypertension, obesity, and dyslipidemia. These 
components are proposed as risk factors for the develop-
ment of prostatic hyperplasia [4,5]. 
In Korea, several studies have reported that men with 
MS had larger prostate volumes [6-8]. So far, however, 
there are insufficient data on the association of MS with 
prostate volume in young Korean men. We therefore inves-
tigated the possible association of MS with prostate volume Korean J Urol 2011;52:757-762
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TABLE 1. Characteristics of the participants
Variables Min Max Mean±SD
Age (yr)
Height (cm)
Weight (kg)
Fasting blood sugar 
(mg/dl)
Systolic blood pressure 
(mmHg)
Diastolic blood 
pressure (mmHg)
Body mass index (kg/m
2)
Abdomen circum-
ference (cm)
Triglyceride (mg/dl)
High-density 
lipoprotein cholesterol 
(mg/dl)
International Prostate 
Symptom Score
Voiding symptom
Storage symptom
Quality of life
Prostate-specific 
antigen (ng/ml)
Total prostate volume 
(ml)
Transitional zone 
volume (ml)
30
153.5
41.9
40
88
47
14.3
60
33
25
0
0
0
0
0.16
9.8
3.0
60
192.3
104.9
418
200
133
34.5
104
719
348
33
20
15
6
3.93
52.3
   28.5
  46.4±8.4
170.7±5.7
  70.4±9.6
    94.7±22.7
  125.7±14.3
    76.2±10.2
  24.3±2.9
  82.4±7.6
  146.5±89.4
    51.6±17.5
    6.5±5.0
    3.8±3.4
    2.8±2.1
    1.7±1.3
    0.84±0.49
  19.9±5.1
    8.2±2.9
in men under the age of 60. 
MATERIALS AND METHODS
1. Study population and data collection
From January 2006 to September 2010, a total of 1,506 men 
aged between 30 and 60 years underwent prostate evalua-
tion as a special option during routine health checkups in 
the Health Promotion Center in our institution. All men 
completed the International Prostate Symptom Score 
(IPSS) questionnaire, a digital rectal examination, trans-
rectal ultrasonography (TRUSG), and anthropometric 
measurements, such as height, weight, and waist 
circumference. Body mass index was calculated by dividing 
weight (kg) by the surface area (m
2) of the patients. The vol-
ume of the prostate was calculated by elliptical volume 
measurement (π/6 x transverse x anteroposterior x cepha-
locaudal diameter), and benign prostate enlargement 
(BPE) was defined as TRUSG-measured prostate volume 
over 20 ml. Blood samples were drawn from fasting pa-
tients to determine fasting blood sugar, high-density lip-
oprotein (HDL) cholesterol, and triglyceride. Self-reported 
information on medical history, major co-morbidities, life-
style, and psychosocial factors as well as symptoms of uro-
logical conditions was also collected. Additionally, we col-
lected information on prostate-related medical or surgical 
treatment history. We excluded 149 men who had a history 
of prostatitis, high prostate-specific antigen (PSA) (≥4 
ng/ml), or abnormal findings on the digital rectal exam or 
TRUSG.
2. Assessment of metabolic syndrome
In this study, MS was defined by using a previously pub-
lished modification of the National Cholesterol Education 
Program Expert Panel on Detection, Evalution, And 
Treatment of High Blood Cholesterol in Adults guidelines 
as the presence of 3 or more of the following 5 character-
istics [9]: 1) waist circumference greater than 90 cm or body 
mass index (BMI) higher than 25 kg/m
2; 2) systolic blood 
pressure 130 mmHg or greater or diastolic blood pressure 
85 mmHg or greater, or antihypertensive medication use; 
3) fasting blood sugar greater than 110 mg/dl or self-re-
ported diabetes medication use; 4) triglyceride greater 
than 150 mg/dl; 5) HDL cholesterol less than 45 mg/dl or 
lipid medication use. As described above, the diagnosis of 
metabolic syndrome, including treated hypertension, dia-
betes mellitus, and hyperlipidemia, was provided by the 
patient’s medical history. In the entry for obesity, BMI and 
waist circumference were applied in the Asia-Pacific 
perspective.
3. Statistical analysis
All statistical analysis was performed by using SPSS ver. 
13.0 (SPSS Inc., Chicago, IL, USA). We divided the study 
population into two groups: the MS group and the non-MS 
group. We compared the IPSS, voiding symptom subscore, 
storage symptom subscore, quality of life (QoL), and pros-
tate-related parameters between the two groups. 
Statistical analysis including Student’s t-test, Pearson’s 
correlation coefficient, and logistic regression analysis was 
performed. Student’s t-test was used to describe the differ-
ence in prostate volume and voiding-related symptom 
score. Pearson’s correlation coefficient was used to test the 
linearity of the relationships between metabolic compo-
nents and prostate volume. We used logistic regression 
analysis to determine the risk factors of BPE. In all compar-
isons of values, p-values of less than 0.05 were considered 
to be statistically significant.
RESULTS
1. Principal patient characteristics
A total of 1,357 men aged 30 to 60 years were analyzed. 
Mean age at baseline in the entire cohort was 46.4±8.4 
years. The age distribution of the patients was as follows: 
389, 481, and 487 men were in their 30s (28.7%), 40s 
(35.4%), and 50s (35.9%), respectively. The median total 
prostate volume and transitional zone volume were 
19.9±5.1 and 8.2±2.9, respectively. The descriptive data, 
including the voiding-related symptom score, QoL, PSA, 
and all anthropometric parameters in the men, are listed 
in Table 1. Korean J Urol 2011;52:757-762
Metabolic Syndrome and Prostate Volume in Young Men 759
TABLE 2. Comparison of the metabolic components and 
symptom scores between the metabolic syndrome group and 
non-metabolic syndrome group
MS group 
(n=354)
NMS group 
(n=1,003)
p-value
Age (yr)
Fasting blood sugar 
(mg/dl)
Systolic blood 
pressure (mmHg)
Diastolic blood 
pressure (mmHg)
Body mass index 
(kg/m
2)
Abdomen circum-
ference (cm)
Triglyceride 
(mg/dl)
High-density 
lipoprotein 
cholesterol (mg/dl)
International 
Prostate Symptom 
Score
Voiding symptom
Storage symptom
Quality of life
Prostate-specific 
antigen (ng/ml)
TPV (ml)
Transitional zone 
volume (ml)
Prevalence of BPE 
  (TPV＞20 ml) (%)
47.0±8.3
104.5±32.8
134.0±13.4
81.5±9.6
26.6±2.5
87.9±6.4
  222.1±108.8
  44.5±18.4
  6.8±5.6
  3.9±3.7
  2.8±2.5
  1.8±1.3
  0.8±0.4
20.6±5.4
  8.8±2.9
54.0
46.2±8.5
  91.2±16.4
122.8±13.4
74.4±9.8
23.5±2.5
80.5±7.0
120.1±63.1
  54.1±16.4
  6.5±4.7
  3.7±3.3
  2.7±2.0
  1.6±1.3
  0.9±0.5
19.7±5.0
  8.0±2.9
38.1
0.104
＜0.001
＜0.001
＜0.001
＜0.001
＜0.001
＜0.001
＜0.001
0.343
0.410
0.373
0.066
0.252
0.004
＜0.001
＜0.001
a
MS: metabolic syndrome, TPV: total prostate volume, BPE: be-
nign prostate enlargement, 
a: χ
2 analysis
TABLE 3. Comparison of the metabolic syndrome group and 
non-metabolic syndrome group according to age distribution
MS group NMS group p-value
30 ≤  Age ≤  40
    IPSS
    Voiding symptom
    Storage symptom
    QoL
    PSA
    TPV
    TZV
40 ＜  Age ≤  50
    IPSS
    Voiding symptom
    Storage symptom
    QoL
    PSA
    TPV
    TZV
50 ＜  Age ≤  60
    IPSS
    Voiding symptom
    Storage symptom
    QoL
    PSA
    TPV
    TZV
4.0±2.6
2.1±1.7
1.9±1.5
1.3±1.2
0.75±0.34
18.6±4.8
7.8±2.2
6.4±3.9
3.5±2.4
2.8±2.0
1.9±1.2
0.85±0.47
20.1±4.5
8.5±2.6
9.1±7.4
5.6±4.8
3.5±3.2
2.1±1.4
0.89±0.52
22.8±5.8
9.9±3.2
3.9±2.9
2.0±1.9
1.9±1.4
1.3±1.2
0.76±0.42
17.6±3.9
6.9±2.1
6.1±3.7
3.5±2.7
2.6±1.7
1.7±1.3
0.89±0.50
19.2±4.5
7.8±2.5
8.9±5.5
5.4±4.0
3.5±2.3
1.8±1.4
0.91±0.57
21.9±5.5
9.2±3.3
0.693
0.709
0.758
0.636
0.827
0.031
＜0.001
0.571
0.873
0.331
0.157
0.400
0.023
0.008
0.774
0.697
0.951
0.067
0.369
0.013
0.042
Satistical analysis by student's t-test, MS: metabolic syndrome, 
NMS: non-metabolic syndrome, IPSS: International Prostate 
Symptom Score, QoL: quality of life, PSA: prostate-specific anti-
gen, TPV: total prostate volume, TZV: transitional zone volume, 
Statistical analysis by Student’s t-test
FIG. 1. Comparison of prostate volume between the metabolic 
syndrome group and the non-metabolic syndrome group. MS: 
metabolic syndrome group, Statistical analysis by Student’s
t-test.
2. Comparisons of variables between the metabolic syn-
drome group and the non-metabolic syndrome group
The prevalence of MS was 26.1%. Subjects with MS were 
older than subjects without MS but not significantly so. The 
mean total prostate volume and transitional zone volume 
of the MS group were larger than those of the non-MS group 
(20.6±5.4 vs. 19.7±5.0, p=0.004, and 8.8±2.9 vs. 8.0±2.9, 
p＜0.001). There was also a significant difference in the 
prevalence of BPE (54.0% vs 38.1%, p＜0.001) (Table 2). 
However, there were no statistically significant differ-
ences between the two groups regarding median age, IPSS, 
voiding and storage subscores, QoL, and PSA. 
Because age is a common risk factor for MS and BPE, we 
performed subgroup analysis by dividing the patients into 
age decades. In all age decades from 30 to 60, prostate vol-
umes were larger with statistical significance in the MS 
group than in the non-MS group (Table 3 and Fig. 1). 
However, no statistical significance was found in the IPSS, 
voiding and storage subscores, QoL, or PSA in the subgroup 
analysis (Table 3). 
3.  Risk factors for benign prostate enlargement
In the univariate logistic regression analysis, age, dia-
betes, obesity, and low HDL were significantly related to 
the presence of BPE. In the multivariate logistic regression 
analysis, only age, diabetes, and obesity were significant 
predictors of BPE (Table 4). Korean J Urol 2011;52:757-762
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TABLE 4. Logistic regression analysis to determine predictors of BPE (TPV＞20 g)
　
Univariate analysis Multivariate analysis
OR 95%CI p-value OR 95%CI p-value
Age
DM
Obesity
LowHDL
HTN
HyperTG
1.084
1.954
1.456
1.508
1.231
1.205
1.068-1.099
1.438-2.654
1.171-1.809
1.196-1.901
0.989-1.532
0.963-1.509
＜0.001
＜0.001
0.001
0.001
0.063
0.103
1.081
1.910
1.441
0.997
1.066-1.097
1.404-2.599
1.144-1.815
0.990-1.004
＜0.001
＜0.001
0.002
0.353
BPE: benign prostate enlargement, TPV:  total prostate volume, OR: odd ratio, CI: confidence interval, DM: diabetes mellitus, LowHDL: 
low high-density lipoprotein cholesterol, HTN: hypertension, HyperTG: hypertriglyceridemia
DISCUSSION
MS is a highly prevalent disorder and has been regarded 
as a risk factor for coronary disease, such as in type 2 dia-
betes mellitus, hypertension, obesity, and hyperlipidemia. 
The principal pathophysiology of MS is secondary hyper-
insulinemia caused by tissue insulin resistance, which 
stimulates the autonomic nervous system, especially the 
sympathetic nerve system, thus resulting in bladder outlet 
obstruction [10,11]. Generally, metabolic components in 
adult males are highly prevalent, and the prevalence in-
creases with increasing age. 
Several studies have suggested that the components of 
metabolic syndrome are risk factors for prostatic hyper-
plasia [12-14]. As early as 1998, Hammarsten et al reported 
the relationship between MS and prostatic hyperplasia 
[12]. In their study, the annual prostate growth rate was 
significantly higher in prostatic hyperplasia patients with 
MS than in prostatic hyperplasia patients without MS. 
Ozden et al studied 78 men with prostatic hyperplasia and 
lower urinary tract symptoms and concluded that the pres-
ence of MS was associated with significantly higher total 
prostate volume and median annual transition zone 
growth rate [14]. Dahle et al reported that some metabolic 
components (such as abdominal obesity and hyper-
insulinemia) are associated with a high risk of prostatic hy-
perplasia [13]. Several Korean studies have also reported 
that men with MS are more likely to have a large prostate 
volume [6-8]. 
Several studies have identified obesity and diabetes as 
risk factors for prostatic hyperplasia [13,15,16]. Parsons et 
al reported a positive relationship between prostate vol-
ume and obesity, elevated fasting plasma glucose, and dia-
betes [15]. Dahle et al also suggested that abdominal obe-
sity and increasing serum insulin level are associated with 
a higher risk of prostatic hyperplasia [13]. The finding that 
men suffering from diabetes and obesity had larger pros-
tate glands than did men without these disorders suggests 
that hyperinsulinemia may be related to the development 
of prostate enlargement, because all these conditions are 
associated with hyperinsulinemia. 
Insulin resistance and secondary hyperinsulinemia con-
stitute important etiologic links between MS and increased 
prostate enlargement. As has been demonstrated in many 
studies, diabetes and hyperinsulinemia are closely related 
[17,18]. Hammarsten et al suggested that prostatic hyper-
plasia may be an insulin resistance condition with secon-
dary hyperinsulinemia as a possible etiological factor for 
prostate enlargement [12]. High insulin levels may induce 
prostatic growth via a variety of mechanisms. One pathway 
that explains the increased risk for prostate enlargement 
in hyperinsulinemia is the insulin-like growth factor (IGF) 
axis. IGF-1 is a strong mitogen and increases cell pro-
liferation and induces apoptosis in many tissues, including 
prostatic stroma and epithelium [4]. Similarly, increased 
glucose levels are likely to be accompanied by hyper-
insulinemia, which results in an increase in insulin-like 
growth factor, a known prostatic mitogen, and induces a re-
duction in proapoptotic cascades within the prostate [5]. 
These changes should culminate in increased prostate 
growth. Furthermore, hyperinsulinemia increases cat-
echolamine levels in plasma and tissues [19], which may 
have a trophic effect on the growth of prostatic cells by 
down-regulating the apoptotic progress, thereby suggest-
ing a link between hyperinsulinemia and the development 
of prostate enlargement. In a previous clinical study, dox-
azosin, an alpha-blocker used for symptomatic prostatic 
hyperplasia treatment, was shown to increase insulin sen-
sitivity and reduce insulin levels [20].
Obesity has been implicated in the etiology of BPE due 
to its influence on metabolic and endocrine changes. 
Adipose tissue, which accumulates with age, aromatizes 
circulating testosterone into testosterone into estrogen, 
and it has been hypothesized that alterations in the bal-
ance between testosterone and estrogen levels in prostate 
tissue with age may contribute to prostate enlargement 
[21]. Abdominal obesity increases the estrogen/androgen 
ratio and may induce sympathetic nervous activity, both 
of which are known to affect the development of prostate 
enlargement and the severity of urinary obstructive symp-
toms [22]. 
The results of previous studies have suggested a possible 
relationship between obesity and prostate enlargement. 
Hammarsten and Högstedt examined 250 men with lower Korean J Urol 2011;52:757-762
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urinary tract symptoms with or without manifestations of 
MS [23]. BMI, waist circumference, hip measurement, and 
the waist/hip ratio were all significantly associated with an 
increased rate of growth of prostatic hyperplasia. Kristal 
et al examined several modifiable lifestyle factors asso-
ciated with the development of symptomatic prostatic hy-
perplasia [24]. They discovered significant increases in 
symptomatic prostatic hyperplasia with abdominal obe-
sity as measured by the waist/hip ratio. Moreover, they also 
suggested that clinical perspective weight loss may prove 
useful for the management of the prostatic hyperplasia 
symptoms. Additionally, men with greater abdominal 
adiposity were reported to be more likely to undergo sur-
gery for prostatic hyperplasia and also to be more likely to 
exhibit frequent obstructive urinary symptoms [22]. The 
results of some Korean studies have suggested that obesity 
is associated with large prostate volume. Kim et al reported 
that patients with an elevated BMI tended to have larger 
prostate volumes [25]. Additionally, Kim et al also reported 
that prostate volume was correlated positively with all obe-
sity-related parameters: BMI, waist circumference, and 
waist-to-hip ratio [26]. In another study, prostate volume 
was greater in the obese groups than in the normal group; 
the results of this study suggested that central obesity (＞90 
cm) is an important risk factor for prostatic hyperplasia (＞20 
ml) [27].
In our study, total prostate volume and transitional zone 
volume in the MS group were significantly larger than in 
the non-MS group. Also, in the subgroup analysis by age 
decades, significant differences in the prevalence of BPE 
were noted. Prostate volumes in the MS groups were sig-
nificantly larger than in the non-MS groups in all age 
subgroups. With increasing age, this trend tends to become 
more evident. The presence of diabetes and obesity were 
also significant risk factors for BPE as measured by 
TRUSG. Although the clinical significance was unclear, 
statistical significance in prostate volume was found even 
in men with metabolic syndrome from as early an age as 
their thirties. 
However, our study has its own limitations. This study 
was conducted in a single institution and may have been 
subject to selection bias. Further large-scale studies in the 
general population will be necessary to confirm our results.
CONCLUSIONS
Metabolic syndrome and prostate volume were sig-
nificantly related even in young males. Diabetes and obe-
sity were identified as significant risk factors for benign 
prostate enlargement in young males under the age of 60. 
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